menu
    • menu
    [{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"ROSS Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"APNmAb005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"APRINOIA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II","highestDevelopmentStatusID":"6","companyTruncated":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II"}]

    Find Clinical Drug Pipeline Developments & Deals by APRINOIA Therapeutics

    Menu

    APRINOIA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            APRINOIA Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            APRINOIA Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APNmAb005

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : ROSS Acquisition Corp II

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Cor...

                            Details : APRINOIA is developing an antibody platform, with APNmAb005 being a novel monoclonal antibody with greater selectivity for pathologic forms of tau that contribute to the pathogenesis of AD and primary tauopathies for the treatment of neurodegenerative di...

                            Product Name : APNmAb005

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 23, 2023

                            Lead Product(s) : APNmAb005

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : ROSS Acquisition Corp II

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth